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Up to 10% of patients with Cystic Fibrosis develop cirrhotic CF-related liver disease with portal 
hypertension: CF cirrhosis (CFC). In a nationwide study, we aimed to determine the role of CFC on 
survival in the Netherlands between 1-1-2009 and1-1-2015. 
Methods  
We identified all CFC patients in the Netherlands, based on ultrasonographic liver nodularity and 
portal hypertension. A non-cirrhotic control group was obtained from the national Dutch CF patient 
registry. We compared groups with regards to baseline lung function and nutritional status and 
survival and age at death over a 6-year period. In case of death of CFC patients, the clinical 
reported cause was recorded. 
Results  
At baseline, we found no significant difference in lung function and nutritional status between the 
CFC patients (N=95) and controls (N=980). Both the 6-year survival rate(77 vs. 93%; P<.01) and 
the median age at death (27 vs. 37 years; P=.02) was significantly lower in CFC compared to 
controls. In the deceased CFC patients, the reported primary cause of death was pulmonary in 
68% of cases, and liver failure related in 18% of cases. 
Conclusions 
In the Netherlands, the presence of CFC is associated with a higher risk for early mortality and an 
approximately 10-year lower median age at death. This substantial poorer outcome of CFC 
patients was not reflected in a lower baseline lung function or a diminished nutritional status. 
However, in the case of mortality, the reported primary cause of death in CFC patients is 
predominantly pulmonary failure and not end-stage liver disease. 
 
Highlights 
 Cystic fibrosis related cirrhosis (CFC) is associated with decreased survival rates in CF 
patients 
 Presence of CFC in CF patients is associated with a 10-year lower median age at death in 
CF patients.  


































































 Elective surgery is a potential risk factor for the progression of stable cirrhosis into acute-
on-chronic liver failure 
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Abbreviations 
BMI: Body mass index  
CFC: Cystic fibrosis related cirrhosis 
CF: Cystic fibrosis 
CFLD: Cystic fibrosis related liver disease 
DIOS: distal intestinal obstruction syndrome  
IQR: interquartile range 
FEV1%: best registered forced Expiratory Volume in the 1st second as percentage of predicted 
value for age, height and gender 






































































Cystic Fibrosis cirrhosis 
Cystic Fibrosis is a common genetic disease with a worldwide incidence of approximately 1 in 3000 
live births.(1) Besides the severe progressive pulmonary disease, cystic fibrosis cirrhosis (CFC) 
could be a common cause of morbidity in CF patients.(2) The reported prevalence of CFC ranges 
from 2 to 10%, depending on the definition. (2-4) 
 
Clinical manifestation of CFC 
CFC is a severe complication of CF, presenting itself in childhood with a peak incidence around the 
age of 10 years.(2,5) The diagnosis of CFC is often established based on routine, periodical 
ultrasound of the liver. CFC is associated with an irregular nodular pattern of the liver parenchyma, 
strongly indicative of the presence of cirrhosis.(6) Additionally, patients often develop clinical and 
biochemical signs of portal hypertension, like splenomegaly and thrombo- and leucocytopenia 
related to hypersplenism. Portal hypertension can be complicated by the development of 
gastrointestinal varices and variceal bleeding episodes.(7) Other complications of CFC include the 
development of ascites, hepatopulmonary syndrome and potentially hepatocellular carcinoma.(8,9) 
CFC is mainly characterized by a stable clinical course, presenting in pediatric age, with severe 
hepatic complications being rare.(10,11) Koh et al. recently reported that, probably as a result of 
the generally improved survival of CF patients, adult-onset CFLD may be more prevalent than 
previously assumed.(12) However, the development of end-stage liver failure is generally 
considered as a sporadic complication in CFC patients.(13) In case of progressive hepatic 
dysfunction, development of ascites and jaundice, intractable variceal bleeding or 
hepatopulmonary syndrome, liver transplantation should be considered in CFC patients.(14) 
 
Mortality in CFC 
There is controversy about CFC reducing life expectancy in CF patients. In the Cystic Fibrosis 
Foundation patient registry of 2016, it was reported that the primary cause of death in CF patients 
in the United States was related to hepatic causes in 2.7% (10/373).(15)  In two separate 
publications, Rowland et al. and Chyrssostalis et al. reported the presence of severe liver disease 
as an independent risk factor for increased mortality in CF.(16,17) However, earlier publications 
from Colombo et al., Gooding et al. and Lindblad et al. did not report CFC as a risk factor for early 


































































other CF disease complications (e.g., pulmonary failure). Although, in a recent study by Ye et al., 
reported that, based ON USCF Foundation Patient Registry data, two-thirds of deaths among 
cirrhotic CF patients were pulmonary related.(7) 
 
The Netherlands  
In the Netherlands, during the observation period, medical care for CF patients was centralized in 8 
certified medical centers with dedicated CF teams. Periodical, yearly, follow up including, among 
other things, blood testing and liver ultrasound after the age of 5 years are included in the standard 
of care in CF. Liver ultrasonographic screening and laboratory testing are used to screen for signs 
of cirrhosis, portal hypertension, and hypersplenism. In the Netherlands liver transplantation for 
CF-related liver failure or irreversible complication of CFC is an accepted indication for liver 
transplantation, and liver transplantation is available for both children and adults.  
 
Dutch CF Registry 
The Dutch CF patient registry was initiated by the Dutch CF foundation in 2007. Anonymized 
patient data is collected on a yearly basis, based on a standard set of variables of CF-related 
disease and health issues. Patient information is collected and provided to the registry by all of the 
8 Dutch care centers. Patient participation is voluntary and is only initiated after written informed 
consent by the patient or their legal representatives. After a run-in period, in 2009, 98% of all CF 
patients in the Netherlands participate in the Dutch CF patient registry. 
  
Aim 
The aim of this study was to assess the prevalence of CFC in the Netherlands, to evaluate the role 
of CFC on (early) mortality and analyze the cause of death. This information could help to provide 
a risk assessment for patients and healthcare professionals, to improve medical care for CFC 





































































We performed a retrospective analysis of the prevalence, survival, and causes of death in CFC 
patients in all eight Dutch CF centers in the Netherlands during the period 1st January 2009 till 1st 




CFC in our study was defined as a documented echogenic inhomogeneous liver with 
splenomegaly or documented histological diagnosis of cirrhosis. Splenomegaly was defined as a 
reported enlarged spleen at physical examination or an ultrasonographic measured spleen size 
above the 95th percentile for gender and age.(19) We identified all CFC patients in the 8 Dutch CF 
care centers alive at 1-1-2009, with a minimum age of 8 years. CFC patients were identified 
directly from medical chart review, on location, in the individual CF care hospitals, based on our 
described definition. In case of mortality in the period 1st January 2009 till 1stJanuary 2015, we 
recorded age at death and retrieved the primary reported cause of death from the medical chart. In 
this study, we focus on the mortality risk of CFC. Patients who had undergone a liver 
transplantation at the start of the observation period were not included the study population.  
 
We composed a control group, from Dutch CF patient registry data from patients aged 8 years and 
older at 1-1-2009. One of the collected variables in this database is ‘liver disease’, of which one 
optional answer is ‘cirrhosis with portal hypertension/hypersplenism’. To compose the control 
group from CF registry, we excluded all patients recorded in the category ‘cirrhosis with portal 
hypertension/hypersplenism’. From the control group, we retrieved data concerning age at death 
and survival in the period 1st January 2009 till 1st January 2015. 11 control patients (1.2%) were 
lost to follow-up during the observation period. 
 
For both CFC and control patients, we obtained lung function parameters in the year 2009 
(FEV1%: as the best registered forced Expiratory Volume in the 1st second as percentage of 
predicted value for age, height and gender (based on: Global Lung Function Initiative 2012) and 
parameters of nutritional status (patients < 18 years: Z-score for body mass index, ≥ 18 years: 





































































Statistical analysis was conducted using SPSS version 22.0. A log-rank test was used to compare 
survival over the 6-year study period between the two groups. Survival data were plotted using the 
Kaplan-Meier method. Lung function parameters, growth parameters and the median age at death 
were not normally distributed and are therefore presented as median with interquartile range (IQR: 
25th percentile – 75th percentile) and analyzed with the Mann–Whitney U test. A P value <.05 was 





































































Baseline patient characteristics, 
From the medical chart review, we identified103 patients that met our CFC definition on 
January 1st, 2009. In two patients CFC was proven by liver histological. Eight patients had 
previously undergone liver transplantation and they were excluded from the analysis regarding 
the median age of death and survival rate.  
The control group, without CFC, consisted of 980 CF patients older than 8 years of age. Based 
on these finding we determined a prevalence of CFC among CF patients, older than 8 years of 
age, on 1st January 2009, in the Netherlands (including patients who underwent liver 
transplantation for CFC) of approximately 10% (103/1083). 
Demographic data regarding gene mutations and gender of study population and controls are 
presented in Table 1. In the CFC group, there was a significantly higher incidence of patients 
homozygous for the F508 del mutation. There was no difference in gender distribution 
between CFC and control patients groups. The median age at baseline was significantly lower 
in the CFC group compared to the control group (18.8 vs. 22.4 years, P<.01). We found that 
all identified CFC patients were treated with ursodeoxycholate (UDCA). There was a 
significantly higher proportion of CFC patients that were reported to use pancreas enzyme 
replacement therapy; an indication of a higher prevalence of exocrine pancreatic insufficiency 
in this population. There was a trend towards a higher representation of CF-related diabetes in 
the CFC group, however, the difference was not significant (p=0.06).  
In children (8-18 years), we found no significant differences in standard deviation scores for 
weight for age (< 18 years) and best annual reported FEV1% at baseline. In adults, we did not 
find significant differences in BMI and/or lung function parameters (FEV1%) in CFC patients 
compared to control patients at the start of the observation period.  
 
Lung transplantation 
At baseline 3 (3%) CFC and 44 (4%) control patients had already received a lung 
transplantation.10/95 CFC patients (10%) and 40/980 control patients (4%) underwent lung 




































































During the study observation period, two patients received a liver transplantation. One patient 
was transplanted (at age 20 years) because of acute-on-chronic liver failure after a lung 
transplantation. One other patient received a liver transplant (at age 19 years), because of 
chronic liver failure (including the development of ascites). Both patients were alive at the end 
of our study observation period.  
 
Survival 
The 6-year survival rate in the period 1st January 2009 – 1stJanuary 2015, was significantly 
lower in the CFC group compared to the control group (77% vs. 93%, P<.01). The Kaplan-
Meier survival curves are shown in Figure 1. The hazard-ratio for 6-year mortality was 4 (95% 
CI: 2-6) in CFC patients compared to control patients.  
 
Age at death 
The median age at death was significantly lower among the deceased CFC patients (27 years, 
n=22) compared to deceased CF patients without CFC (37 years, n=63, P=.02, Table 2).We 
found a more than twofold higher percentage of deceased people in the age range <25 years 
in the CFC group, compared to the control group (45 vs.17%, P<0.01). 
 
Causes of death 
We analyzed the reported causes of death of the 22 deceased CFC patients (Table 3). We 
found that pulmonary failure was reported as the primary cause of death in 15 (68%) cases 
and that liver failure was only reported as the primary cause of death in 4 (18%) cases. One 
24-year old patient died due to end-stage liver failure after a refusal of liver transplantation. 
Three other patients (14%) died after a reported episode of acute-on-chronic liver failure 
following surgical procedures: 2 patients after abdominal surgery for distal intestinal 
obstruction syndrome (DIOS) and one patient following an isolated lung transplantation. In 
none of these 3 patients, liver transplantation was a feasible option at the time of liver failure. 
When looked at lung function tests data of deceased CFC patients during the follow-up period, 
we did not find any rapid decline in lung function tests, in particular also not in the CFC 
patients that, reportedly, died from respiratory failure. Furthermore, median BMI did not differ 



































































We studied the effect of the diagnosis CFC on patient survival in the Dutch CF population. 
This retrospective multicenter analysis is based on a 6-year period (1st January2009 - 
1stJanuary2015) and included all CFC patients alive on 1st January, 2009 in the Netherlands. 
We report that in the Netherlands, the presence of CFC is associated with a significantly 
higher risk for early mortality and an approximately 10-year lower median age at death.  
 
We found that the majority of CFC patients reportedly died of pulmonary causes as the 
primary reason for death. The same observation was recently reported by Ye et al.(7) They 
found, based on data from the Cystic Fibrosis Foundation Patient Registry in the United 
States, that, in a cohort of 943 cirrhotic patients, two-thirds of deaths were reportedly 
pulmonary-related. However, Rowland et al. reported in their study looking at CF-related liver 
disease that died or received a transplant 50% died from pulmonary causes and 50% from 
hepatic causes.(16) They also reported that cirrhotic CF patients who died or received a 
transplant during the year follow-up period had statistically significantly reduced BMI and 
pulmonary function at baseline compared to those who were still alive. We found no baseline 
differences in lung function nor nutritional status between CFC patients and controls.  
Based on study and results, no causal explanation can be given for the relation between CFC 
and the decreased survival and the younger median age at death of these patients. We 
hypothesize that CFC could be an associative risk factor for mortality in situations of 
pulmonary exacerbation or other forms of acute clinical deterioration. Indirect support for this 
hypothesis can be derived from a study by Chyrissostalis et al.(17) They described, based on 
a 15-year follow up study, that liver disease in CF is associated with lower rates for lung 
transplantation-free survival (Hazard-ratio 2.6, p<.01). Another explanation could be that the 
increased mortality is related to a worse nutritional condition described e.g. in cystic fibrosis-
associated liver disease. Corbett et al. reported that children with established cystic fibrosis–
associated liver disease have impaired growth and nutrition, and altered body 
composition.(21) In a recent France study patients with severe CFLD were reported to have 
worse lung function and nutritional status than other CF patients.(22) However, in our study 


































































compared to controls. Our observations therefore do not provide support for improving dietary 
care in CFC patients as a measure to prevent the increased mortality in these patients. 
The increased mortality among CFC patients was particularly striking in the young age group 
of patients below 25 years. Even in this young age group, the primary reported cause of death 
is related to pulmonary failure. The median age at baseline in the CFC patients was lower 
compared to controls. We think this lower median age can be explained by an already 
preexisting early mortality in CFC patients, before the start of our observation period (in 2009). 
Increased existing early mortality in the CFC group will decrease the median of the compared 
to controls.  
The mechanism of how the presence of CFC could affect pulmonary conditions in CF is not 
well understood. Hepatopulmonary syndrome (HPS) is a well-described pulmonary 
complication of CFC in general.(23) Breuer et al. described two CFC patients with 
hepatopulmonary syndrome who had hypoxemia. (9) They suggested that HPS is 
underdiagnosed in patients with CF because of their respiratory morbidity, which could lead to 
hypoxemia. These findings underline the need to be aware of hepatopulmonary syndrome in 
CFC patients in general and regularly check for platypnea/orthodeoxia. However, in our 
current study population, no HPS was described, and none of the CFC patients in this series 
was transplanted because of HPS.  
 
Three of the deceased CFC patients died due to a reported situation of acute-on-chronic liver 
failure following a (non-hepatic) surgical procedure. Furthermore, one patient underwent liver 
transplantation because of the development of acute-on-chronic liver failure after surgery. To 
our knowledge, a correlation between surgery in CFC and mortality has not yet been reported. 
These findings suggest that a surgical (and/or anesthesiological) procedure could be a 
potential risk factor for acute-on-chronic liver failure in CFC patients. The pathophysiological 
mechanism behind this observation is not yet understood but never the less underlines the 
need for awareness in comparable clinical situations and surgery.  
 
The timing of liver transplantation for CFC patients remains an unresolved clinical 
dilemma.(24) Most CFC patients, different from other liver disease, will not develop the classic 


































































primarily die due to pulmonary failure and not hepatic decompensation. It is unclear if early or 
preemptive liver transplantation, in CFC patients without liver function decompensation, will 
prevent early mortality or increase their survival. Liver transplantation as a treatment option 
has its own risks. Black et al. reported, based on data from the United Network for Organ 
Sharing database that liver transplantation in cystic fibrosis is associated with poorer long-term 
patient survival compared to non-cystic fibrosis patients.(25) A survey among European CF 
centers shows that many hospitals perform liver transplantations in CFC patients before the 
development of end-stage liver disease.(26) The reported indications for transplantation were 
hypersplenism, malnutrition, esophageal bleeding, and worsening lung function. The survey 
also showed that there is still a debate regarding the timing of transplantation in relation to the 
development of liver disease and liver function. Currently, in the Netherlands, liver 
transplantation for CFC is generally performed only upon clinical signs of liver failure, e.g., 
synthesis or detoxification disorders or development of hepatopulmonary syndrome. We do 
not know if this policy is related to our findings of decreased survival and lower median age at 
death. The prognosis of preemptive liver transplantation in CFC patients without liver function 
decompensation in comparison vs. no liver transplantation in this population is not known and 
support for preemptive liver transplantation cannot be concluded based on our study or result. 
We feel our results are relevant and important there, however, are some limitations to our 
study may be addressed. Although, we performed a nationwide study, numbers of patients are 
still limited. The data extraction, in particular, the recording of the primary cause of death, from 
the medical charts was performed in a retrospective manner. By using a strict and objectifiable 
definition of CFC we have tried to uniform the study group. The quality of the data in the Dutch 
CF patients registry depends on the interpretation and input of the individual CF care centers. 
We compared lung function and growth parameters of the study groups at baseline. In the 
CFC patients that died, during the observation period, we did see a remarkable decline in lung 
function or nutritional status. However,  we did not have the opportunity to compare lung 
function or the nutritional status of the complete study groups during the observation period. 
Therefore we cannot adjust for the potential confounding effect of the deterioration in lung 
function or nutritional status over time that might explain the worse survival in the CFC group. 
To be able to study the cause of the decreased survival and lower median age of death in our 


































































In conclusion, our study, based medical chart review and data from the Dutch CF patient 
registry, showed that presence of CFC is associated with a 10-year lower median age at 
death, in a country with centralized CF health care and the general availability of liver 
transplantation. Most CFC patients primarily died pulmonary failure and not hepatic failure. 
The cause or causes of decrease survival and lower median age at death in CFC patients are 
not known. However, we feel, given the severity of the difference in survival, additional 
awareness of the increased mortality risk, for instance in a situation of pulmonary 
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Table 1. Baseline patients characteristics 1st January, 2009  
   
 CFC CF without cirrhosis 
   
N 95 980 
Male 52 (55 %) 539 (55%) 
Age at start (years): median (IQR) 19 (15 – 25)  22 (15 – 34)* 























   
   
   
CFTR gene mutations   
Homozygote F508del 59 (62%) 505 (52%)* 
Heterozygote F508del 25 (26%) 358 (37%)* 
Other mutations 9 (9%) 83 (8%) 
Unknown 3 (3%) 34 (3%) 
   
Baseline lung function   
FEV1%(median, IQR) 
 
< 18 years 85 (72.0 - 92.9) 88 (77.4 - 97.5) 
> 18 years 62 (45.6 – 77.0) 61 (43.3 – 80.9) 
FVC%(median, IQR) 
 
< 18 years 90 (79.6 - 104.3) 93 (84.8 - 100.9) 
> 18 years  76 (62.9 – 86.1) 79 (64.6 - 89.6) 
   
Baseline nutritional status    
Z-score weight for height (SD) < 18 years 0.0 (-0.6 - 0.3) -0.1 (-0.7 - 0.4) 
BMI (median, IQR) > 18 years 21 (19 – 23) 22 (20 – 23) 
   
medians with interquartile range (IQR: 25th percentile – 75th percentile) 
*P value <.05 was considered statistically significant(Mann–Whitney U test) 
FEV1:forced expiratory volume in 1 second 
FVC: forced volume vital capacity 










































































Table 2. Age of death and proportion of death per age category 
   
 CFC CF without cirrhosis 
Deceased patients 22 63 
< 25 years 10 (45%) 11 (17%)* 
25-40 years 8 (36%) 28 (44%) 
> 40 years 4 (18%) 24 (38%)* 
 
Median age at death (years) 
 
 













































































Table 3. Distribution of reported cause of death in deceased CFC patients 
 N (%) 
  
Pulmonary failure 15 (68%) 





Non-CF related cause 1 (5%) 











































































Survival rate CFC vs. controle CF patients
Controls (93%)
CFC (79%)*





Figure 1. Survival rate CFC vs. control CF patients 
Kaplan-Meier curve showing the 6-year survival of CFC-patients compared with CF patients 
without CFC in the period 1st January, 2009 till 1st January, 2015. The 6-year survival rate in 
the CFC group was significantly lower compared to the control group (P<0.01).  
 
 
  
 
 
